Clinical trials: Non Alcoholic Fatty Liver
Obesity, Exercise
Structured Exercise Prescription Program in Obese Children
This controlled clinical trial aims to compare the effects of a multicomponent program that includes structured personalized exercise prescription in children with obesity with a control group that will be enrolled in a…
- Conditions
- Obesity, Exercise, Cardiovascular Risk Factor, Liver Diseases
- Trial name
- NCT03552367
- Testing
- Personalized structured exercise program, Non personalized non-structured exercise program
- Where
- Mexico
- Volunteers
- 140 people
- Sponsor
- Hospital General de México Dr. Eduardo Liceaga
Healthy Participants
Study to Assess the Safety, Tolerability, and Pharmacokinetics (Movement of Drugs Within the Body) of AZD2693 in Healthy Participants
This Phase I, randomised, single-blind, placebo-controlled study has been designed to assess the safety, tolerability, and pharmacokinetics (PK) of AZD2693 following subcutaneous (SC) administration of AZD2693 in healthy…
- Trial name
- NCT05107336
- Testing
- AZD2693
- Where
- Japan
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Non-Alcoholic Fatty Liver Disease, Liver Steatosis
Novel Antidiabetic Medications and Their Effect on Liver Steatosis (NAMELS-18)
The goal of this clinical study is to compare the therapeutic effect of Dulaglutide and Empagliflozin in patients with Diabetes Mellitus type 2 and Non-Alcoholic Fatty Liver Disease.
- Trial name
- NAMELS-18 (NCT05946148)
- Testing
- Empagliflozin, Dulaglutide, Control Rx
- Where
- Greece
- Volunteers
- 78 people
- Sponsor
- National and Kapodistrian University of Athens
Non-Alcoholic Fatty Liver Disease, Obesity
Direct Versus Indirect Effect of Amino Acids on Hepatokines
Liver hormones are key metabolic regulators and increased in metabolic diseases, including fatty liver disease. The underlying mechanisms driving the elevated levels are currently unknown and presents a major challenge in…
- Trial name
- Diaakine (NCT06240039)
- Testing
- Evaluating the acute effect of an amino acid infusion with and without a concomitant infusion of the somatostatin analogue octreotide to eliminate endogenous production of glucagon
- Where
- Denmark
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Ulcerative Colitis, Crohn's Disease
Multimodal Approach in IBD Patients
The investigators intend to assess the role of several biomarkers in the prediction of relapse in IBD. Clinical, laboratory and endoscopic data will be gathered and a predictive score will be derived in order to assess the…
- Conditions
- Ulcerative Colitis, Crohn's Disease, Nonalcoholic Fatty Liver Disease (NAFLD), Vitamin D Deficiency
- Trial name
- MAID (NCT01705522)
- Where
- Romania
- Volunteers
- 50 people
- Sponsor
- Clinical Hospital Colentina
Diabete Type 2, Non Alcoholic Fatty Liver
Comparative Effects of Aspirin, Metformin and SGLT2 Inhibitors on Liver Enzymes, Lipid Profile, and FibroScan Findings in Non-Alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD), currently referred to as metabolic dysfunction-associated steatotic liver disease (MASLD), is a common hepatic manifestation of metabolic dysfunction and may progress from simple…
- Trial name
- AS-NAFLD (NCT07338331)
- Testing
- Aspirin, Dapagliflozin (10Mg Tab) along with standard medical therapy, Metformin 1000 mg
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Galala University
Non-Alcoholic Fatty Liver Disease
Screening for NAFLD-related Advanced Fibrosis in High Risk Population in Diabetology.
Nonalcoholic fatty liver disease (NAFLD) is being recognized as one of the most prevalent causes of chronic liver disease worldwide.
- Trial name
- NAFLD-CARE (NCT04435054)
- Testing
- Non-invasive blood-based and imaging-based tests for the screening of NAFLD-related advanced fibrosis.
- Where
- 3 sites in France
- Volunteers
- 1,000 people
- Sponsor
- Hospices Civils de Lyon
Non Alcoholic Steatohepatitis
Efficacy and Safety of Montelukast in Non Alcoholic Steatohepatitis (NASH)
the current study is to evaluate the efficacy and safety of Montelukast in the treatment of patients with non-alcoholic steatohepatitis (NASH).
- Trial name
- NCT04537780
- Testing
- Montelukast
- Where
- Egypt
- Volunteers
- 44 people
- Sponsor
- Tanta University
Non-Alcoholic Fatty Liver Disease, Type 2 Diabetes
Quantifying Hepatic Mitochondrial Fluxes in Humans
In this study the investigators will quantitate hepatic mitochondrial fluxes in T2D patients with NAFL and NASH before and after 16-weeks treatment with the insulin sensitizer pioglitazone
- Conditions
- Non-Alcoholic Fatty Liver Disease, Type 2 Diabetes, Mitochondrial Metabolism Disorders
- Trial name
- NCT05305287
- Testing
- Pioglitazone
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Fatty Liver Disease
Prevalence of Advanced Fibrosis in Patients Living With HIV
Monocentric, cross-sectional study to define the prevalence of advanced fibrosis in an HIV infected outpatient population. Follow-up over 10 years to assess clinical relevance.
- Trial name
- FLASH (NCT04066608)
- Where
- 2 sites in Germany
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Johannes Gutenberg University Mainz
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis), Fatty Liver Disease, Nonalcoholic
Thermoacoustic Method for Estimating Liver Fat Fraction
The goal of this study is to use our Thermoacoustic Enhanced Ultrasound device to measure the fat levels in your liver and compare it to the the gold standard MRI PDFF measurements.
- Trial name
- NCT07321925
- Testing
- Thermoacoustic Enhanced Ultrasound
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Endra Lifesciences
Non-alcoholic Fatty Liver Disease
Effect of Phytosterols on Nonalcoholic Fatty Liver Disease
Phytosterols are plant sterols . Phytosterols have anti-inflammation effect. Investigators have a hypothesis: phytosterols reduce oxidative stress , enhance Insulin-like growth factor-1(IGF-1) and endothelial progenitor…
- Trial name
- NCT01875978
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- China Medical University Hospital
Non-alcoholic Fatty Liver Disease
Silymarin for the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)
This is a randomised study to examine whether high dose Sillymarin will be able to help improve fat-induced liver damage in the liver.
- Trial name
- NCT02006498
- Testing
- Sillymarin
- Where
- Malaysia
- Volunteers
- 99 people
- Sponsor
- University of Malaya
NAFLD
Comparison of the Effects of Metformin and Pioglitazone on Liver Enzymes and Ultrasound Changes in Non-Diabetic Non-Alcoholic Fatty Liver
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a spectrum of hepatic disease ranging from fat accumulation in liver to fibrosis and cirrhosis. It affects 25% of the world population on average.
- Trial name
- NCT05521633
- Testing
- Metformin and Pioglitazone
- Where
- Pakistan
- Volunteers
- 96 people
- Sponsor
- King Edward Medical University
Nonalcoholic Steatohepatitis (NASH)
Study to Evaluate Safety, Tolerability, and Efficacy of GS-0976 in Adults With Nonalcoholic Steatohepatitis
The primary objective of this study is to evaluate the safety and tolerability of firsocostat in adults with nonalcoholic steatohepatitis (NASH).
- Trial name
- NCT02856555
- Testing
- Firsocostat
- Where
- 36 sites in United States
- Volunteers
- 127 people
- Sponsor
- Gilead Sciences
Fibrosis, Liver
Screening for Chronic Liver Diseases in General Population
Improving the care of patients with liver diseases in primary care and will allow patients with chronic liver disease to benefit from a course appropriate care.
- Trial name
- HEPGEN (NCT06366425)
- Testing
- Blood sample then fibroscan
- Where
- France
- Volunteers
- 260 people
- Sponsor
- University Hospital, Montpellier
CKD, NAFLD
Prevalence of Non-alcoholic Fatty Liver Disease in Patients With Chronic Kidney Disease in Assiut
The goal of this observational study is to detect the prevalence of NAFLD in CKD patients The main question[s] it aims to answer are: [question 1] prevalence of NAFLD in CKD patients.
- Trial name
- NCT06009250
- Volunteers
- 200 people
- Sponsor
- Muhammad Ameen Abdelrady Abdelaziz
Non-Alcoholic Fatty Liver Disease
Biological Adaptations of Strength Training.
A two-trial repeated measures design will be employed in this investigation. Both the control trial and the exercise trial will last for 3 months.
- Trial name
- NCT04098484
- Testing
- Control Trial, Exercise Trial
- Where
- Greece
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Democritus University of Thrace
Fatty Liver, Gestational Diabetes
Metabolic Syndrome and Non-alcoholic Fatty Liver During Pregnancy
The aim of this study is to evaluate the prevalence of metabolic syndrome, liver function abnormality and non-alcoholic fatty liver disease in early pregnancy patients, and the risk of pregnancy complications.
- Trial name
- NCT02276144
- Testing
- Liver ultrasound
- Where
- 3 sites in South Korea
- Volunteers
- 2,400 people
- Sponsor
- Seoul National University Hospital
Non-Alcoholic Fatty Liver Disease, Low Birth Weight
Increased Risk of Non-alcoholic Fatty Liver Disease in Low Birth Weight Individuals
The investigators recently demonstrated a increase in liver fat in early middle-aged LBW compared to normal birth weight (NBW) men, and 20% of the LBW - but none of the normal birth weight (NBW) - men had previously unknown…
- Trial name
- NCT05890365
- Where
- Denmark
- Volunteers
- 300 people
- Sponsor
- Steno Diabetes Center Copenhagen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.